Sugi Predict

Sugi Predict / Targets / PNKP

PNKP

Bifunctional polynucleotide phosphatase/kinase · Q96T60 · PNKP on Sugi Atlas →

193 patent compounds predicted against PNKP, 105 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1703545 SCHEMBL1703545 1.00 20/20
SCHEMBL1703560 SCHEMBL1703560 1.00 20/20
SCHEMBL10028432 SCHEMBL10028432 1.00 20/20
SCHEMBL17019712 SCHEMBL17019712 1.00 20/20
SCHEMBL17019725 SCHEMBL17019725 1.00 20/20
SCHEMBL17603648 SCHEMBL17603648 1.00 20/20
SCHEMBL20512281 SCHEMBL20512281 1.00 20/20
SCHEMBL21932969 SCHEMBL21932969 1.00 20/20
SCHEMBL22000250 SCHEMBL22000250 1.00 20/20
SCHEMBL22000255 SCHEMBL22000255 1.00 20/20
SCHEMBL22000257 SCHEMBL22000257 1.00 20/20
SCHEMBL22000393 SCHEMBL22000393 1.00 20/20
SCHEMBL22000400 SCHEMBL22000400 1.00 20/20
SCHEMBL22000401 SCHEMBL22000401 1.00 20/20
SCHEMBL22000402 SCHEMBL22000402 1.00 20/20
SCHEMBL22000405 SCHEMBL22000405 1.00 20/20
SCHEMBL22000412 SCHEMBL22000412 1.00 20/20
SCHEMBL22000414 SCHEMBL22000414 1.00 20/20
SCHEMBL22000426 SCHEMBL22000426 1.00 20/20
SCHEMBL22000557 SCHEMBL22000557 1.00 20/20

Clinical trials — most relevant to PNKP by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Acelarin First Line Randomised Pancreatic Study PHASE2/PHASE3SUSPENDED
A Study of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia PHASE3COMPLETED
A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve) PHASE3WITHDRAWN
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Acetylcarnitine and Insulin Sensitivity PHASE2COMPLETED
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer PHASE1/PHASE2RECRUITING
Assessment of KM-001 - Safety, Tolerability, and Efficacy in Patients With PPPK1 or PC PHASE1COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas PHASE1COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors PHASE1COMPLETED
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers PHASE1COMPLETED
Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy PHASE1COMPLETED
PET Imaging of PARP Activity in Cancer EARLY_PHASE1UNKNOWN
Dried Fruit and Postprandial Glycemia Trial nanUNKNOWN
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer nanUNKNOWN
Biomarker for Hypophosphatasia Disease (BioHypophos) nanWITHDRAWN
Large-scale COVID-19 Population Screening nanUNKNOWN
Evaluation of Thymidine Kinase Activity in the Serum of Patients With Solid Tumors nanUNKNOWN
A Retrospective Study to Identify New Omics Biomarkers of Chronic/Persistent Low Back Pain nanCOMPLETED
Unraveling Genetics of HypoPhosPhatasia (HPP Genetics) nanCOMPLETED
Circulating miRNAs and Bone Microstructure in Adults With Hypophosphatasia nanUNKNOWN
The Role of Sugars in Fat Accumulation in the Liver nanRECRUITING
ProGRP, CgA, NSE and TUM2-PK in in Patients With Neuroendocrine Tumors nanUNKNOWN
Vulvodynia: Identification of Potential Relevant Biomarkers nanCOMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Polycystic Ovary Syndrome in Type 1 Diabetes nanNOT_YET_RECRUITING
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis nanUNKNOWN
Using Next-generation Sequencing in the Diagnosis of Epilepsy and/or Intellectual Disability in a Pediatric Cohorte nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PNKP binder may also engage these)

ProteinNameSimilarity
Q9JLV6 — 0.996 Q9JLV6 →
A5GFZ6 — 0.968 A5GFZ6 →
Q5NVK5 — 0.967 Q5NVK5 →
Q5EA80 — 0.967 Q5EA80 →
A5A779 — 0.967 A5A779 →
TRMT1 tRNA (guanine(26)-N(2))-dimethyltransferase 0.966 landscape →
Q86TX2 — 0.965 Q86TX2 →
Q91YR5 — 0.965 Q91YR5 →
Q8BYL4 — 0.965 Q8BYL4 →
Q5RCE5 — 0.965 Q5RCE5 →
A1A4L8 — 0.965 A1A4L8 →
P85971 — 0.965 P85971 →
Q9Y3E2 — 0.964 Q9Y3E2 →
Q8K2J0 — 0.964 Q8K2J0 →
A5PK19 — 0.964 A5PK19 →
Q5I0L3 — 0.964 Q5I0L3 →
Q9HB07 — 0.964 Q9HB07 →
Q9JHK4 — 0.964 Q9JHK4 →
Q8N6R0 — 0.964 Q8N6R0 →
Q921Q3 — 0.964 Q921Q3 →
Q96EY9 — 0.964 Q96EY9 →
O95396 — 0.964 O95396 →
E1BNQ4 — 0.963 E1BNQ4 →
Q9H6T0 — 0.963 Q9H6T0 →
Q3TX08 — 0.962 Q3TX08 →
Q59I47 — 0.962 Q59I47 →
MAP4K2 Mitogen-activated protein kinase kinase kinase kinase 2 0.962 landscape →
Q58DG1 — 0.962 Q58DG1 →
Q5R7A2 — 0.962 Q5R7A2 →
ALG1 Chitobiosyldiphosphodolichol beta-mannosyltransferase 0.962 landscape →